Reports Q3 revenue $4.21B, consensus $4.04B. “Our sustained high performance is a testament to the strength of our talented global team, differentiated portfolio and category leadership strategy,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific (BSX). “We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX: